| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5200841
Max Phase: Preclinical
Molecular Formula: C11H16N4O5
Molecular Weight: 284.27
Associated Items:
Representations
Canonical SMILES: CC1(C)O[C@@H]2[C@H](O1)[C@@H](CO)O[C@H]2c1n[nH]nc1C(N)=O
Standard InChI: InChI=1S/C11H16N4O5/c1-11(2)19-7-4(3-16)18-8(9(7)20-11)5-6(10(12)17)14-15-13-5/h4,7-9,16H,3H2,1-2H3,(H2,12,17)(H,13,14,15)/t4-,7-,8+,9-/m1/s1
Standard InChI Key: ZFOIPXCVJQZMBS-LPJZALPJSA-N
Associated Targets(Human)
Huh-7.5 200 Activities
Associated Targets(non-human)
Vero 26788 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Zika virus 1028 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 284.27 | Molecular Weight (Monoisotopic): 284.1121 | AlogP: -1.14 | #Rotatable Bonds: 3 |
| Polar Surface Area: 132.58 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 8.31 | CX Basic pKa: | CX LogP: -1.45 | CX LogD: -1.50 |
| Aromatic Rings: 1 | Heavy Atoms: 20 | QED Weighted: 0.64 | Np Likeness Score: 0.60 |
References
| 1. Gonzalez S, Brzuska G, Ouarti A, Gallier F, Solarte C, Ferry A, Uziel J, Krol E, Lubin-Germain N.. (2022) Anti-HCV and Zika activities of ribavirin C-nucleosides analogues., 68 [PMID:35661850] [10.1016/j.bmc.2022.116858] |
Source
Source(1):